Sun Pharma's profit grew where its chemistry is newest
On July 31 Sun Pharma, India's largest drugmaker, reported June-quarter net profit up 27% to 2,895 crore rupees, on revenue up 10% to 15,300 crore.
The growth came from two places: the branded business at home, and the specialty medicines it now sells in the United States. The plain generics that built the company stayed under price pressure.
That is the slow migration in Indian pharma. The margin is moving from copying old molecules cheaply to selling a few new ones dearly.
Specialty products carry patents, marketing muscle and prices that generics cannot hold. Each one that ramps changes the shape of the profit pool more than another generic launch would.
The caveat is concentration. A specialty portfolio leans on a handful of products, so a single approval delay or a rival launch moves the whole quarter.